[Possibility to use venous counter current segments for arteriovenous shunts].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to M Rizzo.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A case of MS with paroxysmal attacks of disarthria, ataxia and double vision is described. The changes in EEG pattern during the attacks, give the opportunity to debate on the pathophysiology of the phenomen.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Internal hernia into epiploic foramen is a rare clinical entity, representing 1% of all herniae and 8% of internal herniae. We report a peculiar case of internal herniation presented during a laparotomy for acute colecystitis where the caecum and ascending colon entered the lesser sac through the forame of Winslow and reentered the main abdominal cavity through a congenital defect of the lesser omentum.
Explore the source record for details and available documents.
We have recently reported the results of a phase I study on the intravesical perfusion of recombinant interleukin-2 in patients with superficial bladder cancer. The treatment feasible with mild toxic effects, especially compared with the treatment using TUR and instillations of Bacillus Calmette-Guerin. The follow-up of these phase I study patients was continued for another twelve months. During this period, cytoscopy and cytological examination of cells washed from bladder were performed every four months. The results showed that three out of 9 patients relapsed, over a period ranging from 6 to 20 months after treatment. All these data clearly confirm that the intravesical perfusion of rIL-2 is feasible, safe and should be an effective and nontoxic treatment of patients with superficial bladder cancer.